Sean D. Keohane
Known title: President and CEOCIK: 0001435737
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Chemours Q2 Earnings Call and UBS Price Target Cut. Chemours released its Q2 2026 earnings call transcript, providing details on its financial performance. UBS kept a neutral stance but lowered its price target to $16, reflecting a more cautious view of the company's outlook. The new target sits below the current average analyst target of $18.22 and near the support level of $15.07, indicating a potential short‑term pressure on the stock.
Transaction History
| CBT | ▲ Buy | Option Exercise | 134,895 | $6.7M | 8/28/2026 | View on chart |
| CBT | ▼ Sell | Open Market | 134,895 | $11.5M | 8/28/2026 | View on chart |
| CBT | ▲ Buy | Option Exercise | 2,779 | $139K | 8/24/2026 | View on chart |
| CBT | ▼ Sell | Open Market | 2,779 | $238K | 8/24/2026 | View on chart |
| CBT | ▲ Buy | Option Exercise | 91,923 | $5.7M | 8/7/2026 | View on chart |
| CBT | ▼ Sell | Open Market | 91,923 | $7.9M | 8/7/2026 | View on chart |
| CC | ▲ Buy | Grant | 7,182 | $0 | 5/6/2026 | View on chart |
| CBT | ▲ Buy | Grant | 32,630 | $0 | 11/19/2025 | View on chart |
| CBT | ▲ Buy | Grant | 30,932 | $0 | 11/19/2025 | View on chart |
| CBT | ▼ Sell | Tax Withholding | 10,338 | $618K | 11/19/2025 | View on chart |
| CBT | ▼ Sell | Tax Withholding | 10,608 | $651K | 11/11/2025 | View on chart |
| CBT | ▼ Sell | Open Market | 2,369 | $189K | 8/14/2025 | View on chart |
| CBT | ▲ Buy | Option Exercise | 87,981 | $4.4M | 8/14/2025 | View on chart |
| CBT | ▼ Sell | Open Market | 80,304 | $6.4M | 8/14/2025 | View on chart |
| CBT | ▼ Sell | Open Market | 7,677 | $611K | 8/14/2025 | View on chart |
| CBT | ▼ Sell | Open Market | 24,086 | $1.9M | 8/14/2025 | View on chart |
| CBT | ▲ Buy | Option Exercise | 26,455 | $1.3M | 8/14/2025 | View on chart |
| CC | ▲ Buy | Grant | 14,096 | $0 | 4/22/2025 | View on chart |
| CBT | ▲ Buy | Grant | 45,842 | $0 | 11/18/2024 | View on chart |
| CBT | ▼ Sell | Tax Withholding | 20,631 | $2.2M | 11/18/2024 | View on chart |
| CBT | ▼ Sell | Tax Withholding | 11,824 | $1.3M | 11/12/2024 | View on chart |
| CBT | ▲ Buy | Grant | 16,957 | $0 | 11/8/2024 | View on chart |
| CBT | ▲ Buy | Option Exercise | 25,617 | $1.0M | 9/3/2024 | View on chart |
| CBT | ▼ Sell | Open Market | 17,865 | $1.8M | 9/3/2024 | View on chart |
| CBT | ▼ Sell | Open Market | 7,752 | $793K | 9/3/2024 | View on chart |
| CC | ▲ Buy | Grant | 8,547 | $0 | 8/6/2024 | View on chart |
| CBT | ▲ Buy | Option Exercise | 17,857 | $822K | 3/1/2024 | View on chart |
| CBT | ▼ Sell | Open Market | 11,278 | $962K | 3/1/2024 | View on chart |
| CBT | ▼ Sell | Open Market | 6,579 | $564K | 3/1/2024 | View on chart |
| CBT | ▲ Buy | Grant | 37,402 | $0 | 11/20/2023 | View on chart |
| CBT | ▼ Sell | Tax Withholding | 39,239 | $3.1M | 11/20/2023 | View on chart |
| CBT | ▼ Sell | Tax Withholding | 16,817 | $1.2M | 11/13/2023 | View on chart |
| CBT | ▲ Buy | Grant | 25,000 | $0 | 11/10/2023 | View on chart |
| CC | ▲ Buy | Grant | 5,858 | $0 | 4/26/2023 | View on chart |
| CBT | ▲ Buy | Grant | 66,196 | $0 | 11/21/2022 | View on chart |
| CBT | ▼ Sell | Tax Withholding | 17,105 | $1.2M | 11/21/2022 | View on chart |
| CBT | ▲ Buy | Grant | 21,939 | $0 | 11/11/2022 | View on chart |
| CBT | ▼ Sell | Tax Withholding | 11,920 | $835K | 11/8/2022 | View on chart |
| CBT | ▲ Buy | Option Exercise | 14,297 | $681K | 5/24/2022 | View on chart |
| CBT | ▼ Sell | Open Market | 939 | $66K | 5/24/2022 | View on chart |
| CBT | ▼ Sell | Open Market | 3,340 | $228K | 5/24/2022 | View on chart |
| CBT | ▼ Sell | Open Market | 10,018 | $695K | 5/24/2022 | View on chart |
| CC | ▲ Buy | Grant | 4,442 | $0 | 4/27/2022 | View on chart |
| CBT | ▼ Sell | Tax Withholding | 9,286 | $554K | 11/22/2021 | View on chart |
| CBT | ▲ Buy | Grant | 57,673 | $0 | 11/22/2021 | View on chart |
| CBT | ▲ Buy | Grant | 24,455 | $0 | 11/12/2021 | View on chart |
| CBT | ▼ Sell | Tax Withholding | 11,975 | $689K | 11/9/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Cabot Corp to Report Q4 FY2026 Results
Cabot Corporation will release its fourth‑quarter and full‑year 2026 operating results on Friday. The announcement follows a period of steady performance and may influence the stock’s near‑term movement. A recent article highlighted the company’s dividend yield of 2.06% and earnings guidance as key factors for investors. The stock is currently trading near its 52‑week low and close to a support level of $74.80.
Cabot Corp to Report Q4 FY2026 Results. Cabot Corporation will release its fourth‑quarter and full‑year 2026 operating results on Friday. The announcement follows a period of steady performance and may influence the stock’s near‑term movement. A recent article highlighted the company’s dividend yield of 2.06% and earnings guidance as key factors for investors. The stock is currently trading near its 52‑week low and close to a support level of $74.80.